IL144188A0 - Compositions for treating inflammatory response - Google Patents

Compositions for treating inflammatory response

Info

Publication number
IL144188A0
IL144188A0 IL14418800A IL14418800A IL144188A0 IL 144188 A0 IL144188 A0 IL 144188A0 IL 14418800 A IL14418800 A IL 14418800A IL 14418800 A IL14418800 A IL 14418800A IL 144188 A0 IL144188 A0 IL 144188A0
Authority
IL
Israel
Prior art keywords
compositions
inflammatory response
treating inflammatory
treating
response
Prior art date
Application number
IL14418800A
Other languages
English (en)
Original Assignee
Univ Virginia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/333,387 external-priority patent/US6232297B1/en
Application filed by Univ Virginia filed Critical Univ Virginia
Publication of IL144188A0 publication Critical patent/IL144188A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14418800A 1999-02-01 2000-01-31 Compositions for treating inflammatory response IL144188A0 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11802999P 1999-02-01 1999-02-01
US12431699P 1999-03-12 1999-03-12
US13337499P 1999-05-10 1999-05-10
US13557399P 1999-05-24 1999-05-24
US09/333,387 US6232297B1 (en) 1999-02-01 1999-06-15 Methods and compositions for treating inflammatory response
US15141299P 1999-08-30 1999-08-30
PCT/US2000/002324 WO2000044763A2 (en) 1999-02-01 2000-01-31 Compositions for treating inflammatory response

Publications (1)

Publication Number Publication Date
IL144188A0 true IL144188A0 (en) 2002-05-23

Family

ID=27557920

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14418800A IL144188A0 (en) 1999-02-01 2000-01-31 Compositions for treating inflammatory response
IL144188A IL144188A (en) 1999-02-01 2001-07-05 History 3 - (Transformed Ethinyl) - Adenosine and their Drug Use

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL144188A IL144188A (en) 1999-02-01 2001-07-05 History 3 - (Transformed Ethinyl) - Adenosine and their Drug Use

Country Status (25)

Country Link
EP (1) EP1150991B1 (https=)
JP (1) JP4837831B2 (https=)
KR (1) KR100668006B1 (https=)
CN (1) CN1191266C (https=)
AR (1) AR029332A1 (https=)
AT (1) ATE263777T1 (https=)
AU (2) AU778870B2 (https=)
BR (1) BR0007864A (https=)
CA (1) CA2361614C (https=)
CZ (1) CZ296404B6 (https=)
DE (1) DE60009665T2 (https=)
DK (1) DK1150991T3 (https=)
EE (1) EE05185B1 (https=)
ES (1) ES2215609T3 (https=)
HU (1) HU228937B1 (https=)
IL (2) IL144188A0 (https=)
MX (1) MXPA01007850A (https=)
MY (1) MY129445A (https=)
NO (1) NO321216B1 (https=)
NZ (1) NZ513096A (https=)
PL (1) PL199953B1 (https=)
PT (1) PT1150991E (https=)
SK (1) SK284877B6 (https=)
UA (1) UA72912C2 (https=)
WO (1) WO2000044763A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
NZ556354A (en) 2001-10-01 2008-10-31 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
US20050033044A1 (en) 2003-05-19 2005-02-10 Bristol-Myers Squibb Pharma Company Methods for preparing 2-alkynyladenosine derivatives
AU2005231440B9 (en) * 2004-04-02 2012-02-23 Dogwood Pharmaceuticals, Inc. Selective antagonists of A2A adenosine receptors
US7396825B2 (en) * 2004-05-03 2008-07-08 University Of Virginia Patent Foundation Agonists of A2A adenosine receptors for treatment of diabetic nephropathy
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
AU2005267706B2 (en) 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
US8178509B2 (en) 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
EP2021350B1 (en) 2006-03-21 2016-12-21 Rheinische Friedrich-Wilhelms-Universität Bonn Phosphorylated a2a receptor agonists
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
AU2007263728A1 (en) * 2006-06-27 2008-01-03 Biovitrum Ab (Publ) Adenosine derivatives for the treatment of pain
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
KR20110028531A (ko) * 2008-07-03 2011-03-18 유니버시티 오브 버지니아 페이턴트 파운데이션 아파데노손의 단위 용량
BRPI1014224A2 (pt) 2009-06-30 2019-09-24 Forest Laboratories Holdings Ltd composto, composição farmacêutica,e, método para tratar um estado.
FR2960876B1 (fr) 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
CN114096552B (zh) * 2019-06-21 2024-09-27 中国人民解放军军事科学院军事医学研究院 具有a2a腺苷受体拮抗作用的小分子化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3537228A1 (de) * 1985-10-19 1987-04-23 Huels Chemische Werke Ag Verfahren zur herstellung von cyclohexylverbindungen
JPS6299330A (ja) * 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd 抗高血圧剤
EP0444196B1 (en) * 1988-11-15 1994-06-08 Yamasa Shoyu Kabushiki Kaisha Agent for treatment and prophylaxis of ischemic disease of heart or brain
ES2077070T3 (es) * 1989-06-20 1995-11-16 Yamasa Shoyu Kk Intermedio de sintesis de 2-alquiniladenosina, produccion de dicho intermedio, produccion de 2-alquiniladenosina a partir de dicho intermedio, y derivado de 2-alquiniladenosina estable.
WO1991009864A1 (fr) * 1990-01-04 1991-07-11 Yamasa Shoyu Kabushiki Kaisha Medicament pour le traitement d'affections ischemiques du c×ur ou du cerveau
JPH03287537A (ja) * 1990-03-31 1991-12-18 Yamasa Shoyu Co Ltd 抗動脈硬化症剤
JP3025559B2 (ja) * 1990-07-19 2000-03-27 ヤマサ醤油株式会社 アデノシン誘導体
JP3025557B2 (ja) * 1991-06-28 2000-03-27 ヤマサ醤油株式会社 ２‐アルキニルアデノシン誘導体
JP3053908B2 (ja) * 1991-06-28 2000-06-19 ヤマサ醤油株式会社 ２‐アルキニルアデノシン誘導体
IT1254915B (it) * 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
AU7449598A (en) * 1997-05-23 1998-12-11 Nippon Shinyaku Co. Ltd. Medicinal composition for prevention or treatment of hepatopathy
AU740770B2 (en) * 1997-06-18 2001-11-15 Aderis Pharmaceuticals, Inc. Compositions and methods for preventing restenosis following revascularization procedures
JPH11335302A (ja) * 1998-05-26 1999-12-07 Toa Eiyo Ltd 安定な医薬組成物
JP3619017B2 (ja) * 1998-06-24 2005-02-09 日本臓器製薬株式会社 新規アラビノシルアデニン誘導体
JP2002173427A (ja) * 1998-09-01 2002-06-21 Yamasa Shoyu Co Ltd 眼疾患治療用医薬組成物

Also Published As

Publication number Publication date
CZ296404B6 (cs) 2006-03-15
EE05185B1 (et) 2009-06-15
WO2000044763A3 (en) 2000-12-14
CN1357002A (zh) 2002-07-03
AU778870B2 (en) 2004-12-23
NO20013507L (no) 2001-09-18
CN1191266C (zh) 2005-03-02
JP2002536300A (ja) 2002-10-29
AU2745400A (en) 2000-08-18
MXPA01007850A (es) 2002-08-20
HUP0200224A3 (en) 2005-02-28
IL144188A (en) 2008-12-29
EP1150991A2 (en) 2001-11-07
KR100668006B1 (ko) 2007-01-15
JP4837831B2 (ja) 2011-12-14
AR029332A1 (es) 2003-06-25
ATE263777T1 (de) 2004-04-15
DE60009665T2 (de) 2004-08-19
DK1150991T3 (da) 2004-06-07
AU2005201255B2 (en) 2008-02-28
CA2361614C (en) 2008-08-26
UA72912C2 (uk) 2005-05-16
DE60009665D1 (de) 2004-05-13
NZ513096A (en) 2003-01-31
BR0007864A (pt) 2001-11-06
PL199953B1 (pl) 2008-11-28
SK10972001A3 (sk) 2002-01-07
HUP0200224A2 (en) 2002-06-29
KR20020013494A (ko) 2002-02-20
NO20013507D0 (no) 2001-07-13
PT1150991E (pt) 2004-08-31
CZ20012781A3 (cs) 2002-01-16
HU228937B1 (en) 2013-06-28
NO321216B1 (no) 2006-04-03
HK1047288A1 (en) 2003-02-14
WO2000044763A2 (en) 2000-08-03
CA2361614E (en) 2000-08-03
MY129445A (en) 2007-04-30
SK284877B6 (sk) 2006-01-05
EP1150991B1 (en) 2004-04-07
EE200100397A (et) 2002-08-15
AU2005201255A1 (en) 2005-04-21
CA2361614A1 (en) 2000-08-03
ES2215609T3 (es) 2004-10-16

Similar Documents

Publication Publication Date Title
HUP0200224A3 (en) Compositions for treating inflammatory response
AU5294100A (en) Method and compositions for treating the inflammatory response
GB9918180D0 (en) Novel compositions
GB9921037D0 (en) Compositions
GB9927315D0 (en) Inhibitor compositions
GB9904049D0 (en) Rapidly-soluble compositions
GB9902520D0 (en) Composition
AP2001002273A0 (en) Rescorcinol composition
GB9903924D0 (en) Cosmectic compositions
GB2366984B (en) Composition
GB9914446D0 (en) Composition
GB9929622D0 (en) Compositions
GB9926833D0 (en) Compositions
GB9904931D0 (en) Compositions
GB2357714B (en) Composition
GB9914582D0 (en) Composition
GB9911933D0 (en) Composition
GB9912422D0 (en) Compositions
GB9920389D0 (en) Compositions
GB9905572D0 (en) Compositions
GB9912421D0 (en) Compositions
GB9905571D0 (en) Compositions
GB9926243D0 (en) Compositions
GB9912423D0 (en) Compositions
GB9904599D0 (en) Compositions